Ondansetron 4MG and 8MG
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D223R0007
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Defense Logistics Agency (DLA) Troop Support has announced its intent to issue a solicitation for a national requirements contract covering the supply of Ondansetron Hydrochloride (HCL) in both 4MG and 8MG tablet formulations, including both standard and orally disintegrating tablets. This procurement is structured as a presolicitation notice under procurement identifier SPE2D223R0007, with the anticipated solicitation to be posted on the DLA Bid Board System (DIBBS) and SAM.gov.
The primary objective of this procurement is to establish a reliable, national supply source for Ondansetron HCL 4MG and 8MG tablets to meet the ongoing needs of multiple federal healthcare entities. The contract will support the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, facilitating their access to these critical pharmaceutical products through the DLA and VA prime vendor programs. The contract is designed as a firm-fixed price, requirements-type agreement, featuring a one-year base period with four additional one-year option periods, ensuring continuity of supply and pricing stability over a potential five-year term.
This acquisition is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), with Product Service Code 6505, indicating its focus on pharmaceutical products. The procurement is unrestricted and fully competitive, inviting proposals from all qualified sources. The solicitation will be conducted in accordance with FAR Part 12 procedures for commercial items, and the resulting contract will adhere to FAR 52.216-21 (Requirements), obligating the contractor to fulfill all orders placed by the participating agencies during the contract period.
Key requirements include the ability to manufacture and supply Ondansetron HCL in both 4MG and 8MG strengths, in both standard and disintegrating tablet forms, at a national scale. Annual usage estimates and detailed product specifications will be provided in the Schedule of Supplies section of the solicitation. Offerors must be capable of meeting the quality, regulatory, and delivery standards expected for federal pharmaceutical contracts.
Interested parties are encouraged to monitor the DIBBS and SAM.gov websites for the official release of the solicitation and any subsequent updates. The projected solicitation date is March 2023, though DLA reserves the right to adjust this timeline as necessary. All inquiries regarding this opportunity should be directed to the primary contact, Christopher Newman ([email protected], 215-737-2905), or the secondary contact, Jason Wray ([email protected], 215-737-0614).
This opportunity represents a significant, long-term contract for pharmaceutical manufacturers and distributors with the capacity to support large-scale, multi-agency federal requirements. There are no set-aside restrictions, and all responsible sources are invited to submit proposals, which will be fully considered by the agency. Contractors are advised to set up automated notifications for updates related to this solicitation.
For further details and to access the solicitation once posted, interested vendors should visit the official notice at: https://sam.gov/opp/78991b7acb26473fb3df647f2a7cc6a8/view.
Documents7